Infliximab and Ulcerative Colitis

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease. The condition causes the colon and rectum to become inflamed and ulcerated.

Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

Ulcerative colitis - The Lancet

REMICADE® (infliximab) for Moderately to Severely Active Adult UC

Ulcerative colitis: management in adults, children and young people – concise guidance

ARCH Study: Higher Doses of Infliximab in Acute Severe Ulcerative Colitis

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis

Infliximab News, Research

Management of moderate to severe ulcerative colitis - American Gastroenterological Association

Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis - ScienceDirect

Infliximab Pharmacology

JCM, Free Full-Text

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience, BMC Gastroenterology

Dosing & Administration REMICADE® (infliximab) HCP

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience, BMC Gastroenterology